Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 19 October 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Genetic features of aflatoxin-associated liver cancer

This month's issue of Gastroenterology investigates the genetic features of aflatoxin-associated HCC that can be used to differentiate them from HCCs not associated with this carcinogen.

News image

Dietary exposure to aflatoxin is an important risk factor for hepatocellular carcinoma (HCC).

However, little is known about the genomic features and mutations of aflatoxin-associated HCCs compared with HCCs not associated with aflatoxin exposure.

Dr Yi-Xin Zeng and colleagues from China investigated the genetic features of aflatoxin-associated HCC that can be used to differentiate them from HCCs not associated with this carcinogen.

The researchers obtained HCC tumor tissues and matched non-tumor liver tissues from 49 patients, collected from 1990 through 2016, at the Qidong Liver Cancer Hospital Institute in China—a high-risk region for aflatoxin exposure.

Somatic variants were identified using GATK Best Practices Pipeline.

The research team validated part of the mutations from whole-genome sequencing and whole-exome sequencing by Sanger sequencing.

The team also analyzed genomes of 1072 HCCs, obtained from 5 datasets from China, the United States, France, and Japan.

Mutations in 49 aflatoxin-associated HCCs and 1072 HCCs from other regions were analyzed using the Wellcome Trust Sanger Institute mutational signatures framework with non-negative matrix factorization.

The mutation landscape and mutational signatures from the aflatoxin-associated HCC and HCC samples from general population were compared.

The researchers identified genetic features of aflatoxin-associated HCC, and used these to identify aflatoxin-associated HCCs in datasets from other regions.

Tumor samples were analyzed by immunohistochemistry to determine microvessel density and levels of CD34 and CD274.

The researchers found that aflatoxin-associated HCCs frequently contained C>A transversions, the sequence motif GCN, and strand bias.

In addition to previously reported mutations in TP53, the team found frequent mutations in the adhesion G protein−coupled receptor B1 gene (ADGRB1), which were associated with increased capillary density of tumor tissue.

The team observed that aflatoxin-associated HCC tissues contained high-level potential mutation-associated neoantigens, and many infiltrating lymphocytes and tumors cells that expressed PD-L1, compared to HCCs not associated with aflatoxin.

Of the HCCs from China, 10% contained the aflatoxin-associated genetic features, whereas less than 1% to 4% of HCCs from other regions contained these genetic features.

Dr Zeng's team concludes, "We identified specific genetic and mutation features of HCCs associated with aflatoxin exposure, including mutations in ADGRB1, compared to HCCs from general populations."

"We associated these mutations with increased vascularization and expression of PD-L1 in HCC tissues."

"These findings might be used to identify patients with HCC due to aflatoxin exposure, and select therapies."

Gastroenterol 2017: 153(1): 249–262.e2
21 July 2017

Go to top of page Email this page Email this page to a colleague

 19 October 2017 
Current management of chylous ascites
 19 October 2017 
Fecal immunochemical tests in colorectal cancer screening
 19 October 2017 
Surgical anastomosis at 1-year colorectal cancer surveillance
 18 October 2017 
Hep E seroprevalence and hemodialysis
 18 October 2017 
Prebiotic and changes in the human gut microbiota
 18 October 2017 
Predicting recurrence after curative rectal cancer surgery
 17 October 2017 
Laparoscopic surgery use in Medicare patients with colon cancer
 17 October 2017 
Medication nonadherence and health care costs
 17 October 2017 
Asthma and IBD development
 16 October 2017 
Colorectal cancer screening and postpolypectomy surveillance colonoscopy
 16 October 2017 
Continuity of care after colorectal surgery
 16 October 2017 
Breastfeeding and the risk of IBD
 13 October 2017 
Treating patients with HCV and severe renal impairment
 13 October 2017 
Blood pressure management during abdominal surgery
 13 October 2017 
Food elimination diets for eosinophilic esophagitis
 12 October 2017 
Global recurrence of H. pylori
 12 October 2017 
Colonoscopy in an organized colorectal cancer screening program 
 12 October 2017 
Predicting advanced fibrosis in chronic hepatitis B
 11 October 2017 
Fecal microbiota transplantation for ulcerative colitis
 11 October 2017 
Sexual functioning in Hep C
 11 October 2017 
Ulcerative proctitis in pediatric-onset UC
 10 October 2017 
Quality standards in upper gastrointestinal endoscopy
 10 October 2017 
Eosinophilic esophagitis and swallowed topical corticosteroids
 10 October 2017 
Follow-up of positive results on fecal blood tests
 09 October 2017 
Diverticulitis and emergency department burden
 09 October 2017 
Clostridium difficile infection after ileostomy reversal
 09 October 2017 
Global recurrence rate of H. pylori
 06 October 2017 
Predicting nontreatment for Hep C
 06 October 2017 
Cow's milk–based formula and development of celiac disease
 06 October 2017 
Propofol for outpatient colonoscopy
 05 October 2017 
Pediatric candidates on the transplant wait list
 05 October 2017 
Incidence of sepsis in the USA
 05 October 2017 
Quality of life after chemoradiation in rectal cancer
 04 October 2017 
Peptic ulcer disease diagnosed in acute upper endoscopy
 04 October 2017 
Clinical practice guidelines in colon cancer
 04 October 2017 
Rural residence and risk of IBD
 03 October 2017 
Novel candidate risk genes for IBD
 03 October 2017 
Antibody tests and detecting celiac disease
 03 October 2017 
Environmental factors and IBD
 02 October 2017 
Full publication of Gastroenerology abstracts
 02 October 2017 
Interferon-free therapy in advanced liver disease
 02 October 2017 
Burden of NAFLD with advanced fibrosis in the USA
 29 September 2017 
Inpatient Gastroenterology training experience
 29 September 2017 
Proteomic analysis of IBD
 28 September 2017 
Incidence of biopsy-verified celiac disease
 28 September 2017 
Social networking-based discussion group by ERCP doctors
 27 September 2017 
Function of trypsin-3 in IBS
 27 September 2017 
Predictors of nonadherence in IBD
 27 September 2017 
Hep C treatment in the era of direct-acting anti-viral agents
 26 September 2017 
Chronic pancreatitis and pancreatic cancer risk
 26 September 2017 
Factors associated with the risk of metachronous gastric neoplasm
 26 September 2017 
Treatment of hyperactive delirium in advanced cancer
 25 September 2017 
Lenalidomide for advanced liver cancer
 25 September 2017 
Silibinin nanoparticles inhibit HCV infection
 22 September 2017 
Perforation after colonic endoscopic mucosal resection
 22 September 2017 
Medical management and colectomy rates
 22 September 2017 
MRI for liver metastatic colorectal cancer
 21 September 2017 
Adenomatous colorectal polyps in young cancer survivors
 21 September 2017 
Predicting mucosal healing in treated celiac disease patients
 21 September 2017 
Antireflux surgery and recurrence of GERD

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us